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ABSTRACT
The involvement of non-coding RNAs (ncRNAs) in cellular physiology and disease 
pathogenesis is becoming increasingly relevant in recent years specifically in cancer 
research. Breast cancer (BC) has become a health concern and accounts for most of 
the cancer-related incidences and mortalities reported amongst females. In spite of 
the presence of promising tools for BC therapy, the mortality rate of metastatic BC 
cases is still high. Therefore, the genomic exploration of the BC subtype and the use 
of ncRNAs for possible regulation is pivotal. The expression and prognostic values 
of AURKA gene were assessed by Oncomine, GEPIA, KM-plotter, and bc-GenExMiner 
v4.4, respectively. Associated proteins and functional enrichment were evaluated 
by Cytoscape and DAVID databases. Additionally, molecular docking approach was 
employed to investigate the regulatory role of hsa-miR-32-3p assisted argonaute 
(AGO) protein of AURKA gene in BC. AURKA gene was highly expressed in patients 
with BC relative to normal counterpart and significantly correlated with poor survival. 
The docking result suggested that AURKA could be regulated by hsa-miR-32-3p as 
confirmed by the reported binding energy and specific interactions. The study gives 
some insights into role of AURKA and its regulation by microRNAs through AGO 
protein. It also provides exciting opportunities for cancer therapeutic intervention.
INTRODUCTION
Breast cancer (BC) is the most frequently diagnosed 
cancer among females and accounts for most of the 
cancer-related incidences and mortalities [1] Globally, 
statistics have shown massive increase in incidence and 
mortalities from 1.7 million and 521,900 to 8.6 million 
and 4.2 million in BC, respectively [1, 2]. Approximately 
one in eight women will be diagnosed with invasive BC 
in their lifetime and one in 39 women will die from BC 
[3]. There are increasing attempts in cancer research to 
correlate molecular subtypes of BC in order to tailor 
treatment and develop new therapies [4]. Based on BC 
molecular subtypes, luminal A tumor appears to present 
better prognosis, have high survival rate and reduced 
chances of recurrence [5–7]. Currently used markers in the 
management and prognostic of BC do not equate accurate 
prediction of how individuals will respond to prescribed 
treatment of each subtype and their survival thereof. The 
poor survival and high mortality rates in BC are in part 
due to lack of effective BC prognostic biomarkers. It is 
therefore necessary to identify novel biomarkers that can 
serve as targets for BC therapeutic intervention.
More so, genomic exploration has been employed to 
identify novel gene regulators or roles of pre-existing gene 
members in signaling pathways [8]. In the same fashion, 
this advancement can be deployed in cancer research to 
sort out genetic alteration in order to tailor therapeutic 
responses most especially in BC [9].
The human protein kinases are fascinating targets 
for the discovery of novel cancer therapy due to their 
crucial role in cancer development and progression, and 
other related processes such as metabolic diseases [10, 11]. 
Aurora A kinase (officially: AURKA; aliases: Aurora-2, 
RKI, and STK15) is a conserved serine/threonine kinase 
which belong to the superfamily aurora kinase (AK). 
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The AK primarily functions by regulating key cellular 
functions including mitosis and signaling pathways. The 
dysfunction of AK may result in mitotic arrest, aneuploidy, 
and apoptosis. Increased expression or amplification of 
AURKA is common in most human cancers including 
BC [12–18]. AURKA has been established as a legit 
oncogene and thus, a vital therapeutic target in cancer 
[19]. Its expression has been shown to be modulated by 
small molecules including microRNAs in cancers [20–23].
Non-coding RNAs (ncRNAs) have been thought 
to regulate the expression of target genes at post-
translational level. The relevance of these ncRNAs 
particularly microRNAs and ncRNAs as therapeutic 
targets and delivery strategies in clinical translation were 
investigated for their involvement in cancer and related 
diseases. Diverse approaches have both in the past and 
recently been employed by researches to comprehend the 
complexity of BC.
Previous studies indicated that miR-32 may be 
tumor suppressive in nature [24, 25] and its regulatory 
effect on AURKA have been shown in various cancer 
subtypes [19, 26–29].  Due to their regulatory role in the 
expression of tumor associated genes at post-translational 
level [30, 31], we proposed that human argonaute protein 
(hAgo2) may regulate the expression of AURKA via hsa-
miR-32-3p. Although the complexity of BC subtypes is 
correlated with molecular and genetic information from 
tumor cells, prognosis and therapeutic managements are 
monitored mainly by tumor stage, grade, hormone receptor 
status and HER2 status. Therefore, in silico and molecular 
docking studies were used to investigate the expression 
of AURKA gene in relation to its clinicopathological 
characteristics and the mechanism of regulation through 
hsa-miR-32-3p assisted hAgo2 in BC.
RESULTS
Expression of AURKA in cancers
Using Oncomine database, AURKA expression was 
identified in various human cancers, in both hematological 
malignancies and solid tumors (Figure 1A). The mRNA 
levels of AURKA were significantly upregulated in BC 
patients in 11 datasets and down-regulated in 1 dataset. 
Furthermore, the GEPIA dataset revealed that the mRNA 
expression level of AURKA was significantly higher in BC 
tissues than in normal breast tissues (Figure 1B). In Curtis 
Breast Statistics’ dataset, AURKA was overexpressed 
compared to normal samples in all breast cancer types 
(Figure 2). In Zhao Breast Statistics’ dataset, AURKA was 
overexpressed in invasive ductal breast cancer and lobular 
BC (Figure 2). In TCGA Statistics’ dataset, AURKA was 
overexpressed in all the samples (Figure 2) while down-
regulation was observed in the Finak Breast Statistics’ 
dataset in invasive BC with fold change of -11.071 
compared to the normal samples. As shown in Table 1, the 
transcription levels of AURKA in different BC types were 
also higher than those in normal breast tissues at P < 0.05. 
Survival analysis of AURKA in BC
The prognostic significance of AURKA was 
assessed in all BC datasets using KM-plotter (Figure 3). 
The increased AURKA mRNA level was strongly 
associated with poor overall survival (OS), post-
progression survival (PPS), distant metastasis free survival 
(DMFS) and recurrence-free survival (RFS). To validate 
this result, PrognoScan database was employed. The 
PrognoScan revealed that high expression of AURKA was 
significantly associated with poor OS, DFS, higher risk 
of distance metastasis and relapse at p < 0.05 (Figure 4A 
and 4B).
Prognostic values of AURKA in BC patients with 
different clinicopathological features
The association of AURKA gene with other 
clinicopathological features (such as; ER, PR, HERS2, 
lymph node status, TP53 status, as well as the BC’s 
pathological and clinical grades), and its correlation 
with these clinicopathological features was assessed in 
BC (Table 2). The mRNA expression level of AURKA 
was correlated with OS and DMFS of all patients with 
BC. In terms of ER status, increased mRNA expression 
of AURKA was associated with longer DMFS in ER-
negative, but high mRNA expression of AURKA was 
linked to poor OS and DMFS in ER-positive and OS in 
ER-negative in BC patients. For ER status, increased 
expression was associated with poor prognosis both 
positive-ER in OS and DMFS and in negative-ER in 
OS. Only the ER-positive was related to better survival 
in DMFS. Conversely, the mRNA levels of AURKA is 
significantly higher in human epidermal growth factor 
receptor 2 (HER2) positive BC patients compared with 
the HER2-negative ones. Although there is significant 
correlation between the two subtypes, increased 
expression was associated with good prognosis in HER2-
positive in both OS and DMFS while poor survival was 
observed in HER2-negative in OS and DMFS. For clinical 
lymph node status in BC patients, high mRNA expression 
of AURKA was associated with poor OS and DMFS in 
the subgroups (positive and negative nodal status). The 
high expression of AURKA mRNA was associated with 
improved OS and poor DMFS in pathological grade 
I BC patients; and poor OS and DMFS in pathological 
grade II BC patients. However, there is no significant 
association of AURKA with prognosis in grade III BC 
patients. Mutation of TP53 in cancers, including BC, is 
very common [32]. Its wild type codes for p53 which is 
involved in a number of physiological functions such as 
cellular senescence, metabolism, DNA repair, cell cycle 
arrest, programmed cell death, and many other processes 
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following cellular stress [33]. Mutated TP53 may cause 
BC to metastasize as a result of altered p53 protein, 
which in turn fails to recognize and trigger apoptosis in 
cells with mutated genes. TP53 mutations are a negative 
prognostic factor in BC (Varna et al., 2011). Tumors with 
TP53 mutations are more likely to be aggressive (triple-
negative (basal-like) or HER-2-positive (Luminal-B) BC) 
[34–36]. High mRNA expression level of AURKA was 
associated with poor OS and DMFS in wide type TP53 
BC. However, high expression levels of this gene were not 
correlated with mutated-TP53-type BC. The welch’s test 
(bc-GenExMiner) was further used to analyze the subtypes 
of each clinicopathological features. 
Genetic alterations of AURKA and 
clinicopathological parameters in BC patients
As depicted in Table 3, the transcription levels of 
AURKA were compared by bc-GenExMiner using the 
welch’s test among BC patients associated with some 
clinicopathological parameters [37]. These parameters 
include the age of the patient, together with statuses on the 
disease nodal, absence or presence of BC receptors, TP53, 
and so on. For age criterion, high expression of AURKA 
was significantly associated with patients above 51 years 
compared to patients below the age of 51 years. Also, BC 
patients with positive nodal status, mutated-TP53, basal-
like and triple negative BC (TNBC) status had higher 
AURKA mRNA compared to those with negative-nodal, 
wild type-TP53, not-basal-like and not-TNBC statuses 
(Table 3). Receptor statuses (PR and ER) were negatively 
correlated with the AURKA expression. On the contrary, 
the AURKA mRNA levels were significantly increased 
in BC patients with higher expression levels of HER2 
compared to the HER2-negative subtype (Table 3). In 
Sorlie’s intrinsic molecular subtypes, the components were 
associated with the higher mRNA level of AURKA but the 
basal-like and luminal B has no difference with respect to 
elevated level of AURKA (Figure 5).
Gene association of AURKA
The importance of PPis have been reported 
in biological processes and cellular function in both 
prokaryotes and eukaryotes including humans (normal 
and disease states) [38]. Identification of protein partners 
for AURKA can be an important lead to unravel the 
mechanisms of action for diseases typically cancer 
Figure 1: The transcription levels of AURKA in different types of cancers (Oncomine). The graphic demonstrated the numbers 
of datasets with statistically significant mRNA over-expression (red) or down-expression (blue) of the target gene. (A) the expression of 
AURKA in 20 datasets (Oncomine). (B) the expression of AURKA in BC (GEPIA). The threshold was designed with following parameters: 
Threshold (p-value): 1.0 × 10-6; threshold (fold change) × 2; and gene rank of top 5%; TPM: Transcript per million. Abbreviations: GEPIA, 
Gene Expression Profiling Interactive Analysis.
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and further generate therapeutic drugs and treatment 
advancement. Numerous experimental approaches have 
been used for the discovery of interacting genes but the 
processes are demanding with limited outputs. However, 
computational approach has been increasingly used to 
validate and predict hidden protein partners. This study 
identified 10 proteins associated with AURKA genes 
through curated database entries, experimental validation, 
text mining, co-expression and or protein homology since 
proteins are constantly regulated and rarely function in 
isolation (Figure 6). These genes are crucial to the roles 
and specific molecular network of AURKA in disease, 
most importantly BC. The 10 associated proteins identified 
for AURKA at p < 0.05 include: Polo like kinase 1 
(PLK1), centromere protein A (CENPA), DLG associated 
protein 5 (DLGAP5), TPX2, microtubule nucleation 
factor (TPX2), aurora kinase A (AURKA), baculoviral 
IAP repeat containing 5 (BIRC5), cell division cycle 20 
(CDC20), cyclin B2 (CCNB2), cyclin dependent kinase 1 
(CDK1), transforming acidic coiled-coil containing protein 
3 (TACC3), ubiquitin conjugating enzyme E2 C (UBE2C), 
have a PPI enrichment p-value of 2.74 × 10-13, average node 
degree of 10 and average local clustering coefficient of 1.0. 
Further studies to give insights into the relationship of each 
Table 1: AURKA mRNA expression level in BC compared to normal tissues (Oncomine) in 12 
datasets
BC Subtype Fold-change P-value Rank (%) Sample Source
Ductal BC 9.423 1.18 × 10-14 1 47 (Richardson et al., 2006)
Medullary BC 4.706 7.88 × 10-19 1 2136 (Curtis et al., 2012)
Invasive Ductal BC 3.168 4.88 × 10-120 1 2136 (Curtis et al., 2012)
Invasive Lobular BC 2.115 5.80 × 10-44 2 2136 (Curtis et al., 2012)
Invasive Ductal & Invasive Lobular BC 2.339 1.02 × 10-31 2 2136 (Curtis et al., 2012)
Invasive BC 2.586 9.96 × 10-7 3 2136 (Curtis et al., 2012)
Mucinous BC 2.137 8.28 × 10-16 3 593 TCGA, 2011
Invasive Ductal BC 4.702 5.39 × 10-53 1 593 TCGA, 2011
Invasive BC 3.468 5.83 × 10-26 1 593 TCGA, 2011
Invasive Lobular BC 2.351 7.20 × 10-14 2 64 TCGA, 2011
Invasive Ductal BC 2.154 2.34 × 10-7 4 64 (Zhao et al., 2004)
Invasive Breast Carcinoma Stroma –11.071 2.11 × 10-30 2 59 (Finak et al., 2008)
Notes: P-value was analyzed using the t-test. The P-values indicate that the difference was statistically significant between the BC and normal tissue group. 
Abbreviations: BC, breast carcinoma. mRNA levels of AURKA in different subtypes of BC.
Table 2: The prognostic values of AURKA in BC patients with different clinicopathological features 
(Kaplan–Meier plotter: dataset 208079_s_at)
AURKA Clinicopathological OS DMFS
features Case HR 95% CI p-value Case HR 95%CI p-value
Overall 1402 2.12 1.64–2.74 4.2 × 10–9 1746 1.87 1.54–2.27 1.0 × 10-10
ER stat ER (+) 548 2.2 1.54–3.13 7.7 × 10–6 664 2.74 1.96–3.82 8.4 × 10-10
ER (–) 251 1.33 0.83–2.12 0.23 218 0.54 0.34–0.85 0.0072
PR stat PR (+) 83 4.1 0.1–5.99 0.02 192 4.41 1.13–14.83 0.0088
PR (–) 89 2.7 0.96–7.57 0.05 154 0.66 0.34–1.27 0.21
HER2 HER2 (+) 129 0.37 0.15–0.9 0.023 126 0.42 0.21–0.83 0.0096
HER2 (–) 130 8.33 1.12–62.17 0.013 150 3.11 1.31–7.38 0.0068
LN stat LN (+) 313 1.59 1.05–2.42 0.029 382 1.78 1.21–2.63 0.0031
LN (–) 594 2.23 1.53–3.25 1.7 × 10–5 988 2.3 1.74–3.02 1.0 × 10-9
Grade I 161 4.888 1.41–16.9 0.0057 188 4.5 1.66–12.26 0.0013
II 387 2.02 1.31–3.11 0.0012 546 2.2 1.56–3.12 4.8 × 10-6
III 503 1.35 0.97–1.87 0.074 458 1.22 0.86–1.73 0.27
TP53 Mutated 111 0.42 0.12–1.39 0.14 83 0.37 0.11–1.25 0.095
Wide type 187 3.36 1.31–8.63 0.0075 109 2.8 1.28–6.12 0.0071
Notes: P-value was analyzed using the survival analysis test. The bold font indicates that the difference was statistically significant. Abbreviations: ER stat: Estrogen 
status; PR stat: progesterone status; LN stat: lymph node status; +: positive; –: negative; TP53 mut: HER2: human epidermal growth factor receptor 2; TP53 
mutation; OS: overall survival; DMFS: distance metastasis free survival; BC: breast cancer. Clinicopathological association of AURKA with prognosis in BC.
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of the identified genes with respect to AURKA expression 
in BC, is highly recommended.
Functional enrichment and pathway analysis
The discovery of pathways and specific processes 
that are significant with factors regulating activities 
to genes of interest is important in cancer research. 
To identify functional categories and characteristic 
biological attributes of associated genes, gene oncology 
(GO) enrichment analysis was performed using 
DAVID database. DAVID gives a high-throughput 
and attractive data collection condition, and merge the 
functional genomic annotations with intuitive graphical 
representations encouraging the transition between 
genomic information and the biological meaning. The 
GENETIC_ASSOIATION_DB_DISEASE analysis was 
employed to evaluate AURKA gene targets associated 
with BC from the setup installation file of the genes 
from STRING database. Additionally, GO provides 
classifications of genes in relation to their molecular and 
cellular structures and functions [39]. 
The three categories of GO terms include the 
biological process (BP), cellular component (CC), and 
molecular function (MF). The KEGG pathway in DAVID 
also contains adequate information of known metabolic 
and regulatory pathways and accelerates the mapping of 
genes to KEGG pathways for systemic analysis of gene 
functions [40].
To explore the functions as well as the pathways 
crucial to the associated genes in relation to BC, GO and 
KEGG pathway enrichment analyses were carried out for 
Table 3: The relationship between mRNA expression of AURKA and clinicopathological features 
of BC
AURKA
Variables Case mRNA p-value
Age 0.0001
≥ 51 1387 ↑















Wild Type 523 —
Basal-Like Status 0.0001
Basal-Like 962 ↑






Note: ER: estrogen; PR: progesterone; HER2: human epidermal growth factor receptor 2; (+): positive; (–): negative; TP53: 
tumor protein 53; TNBC: triple-negative BC. The significant different between groups was assessed by Welch’s test to 
generate p value, along with Dunnett-Tukey-Kramer’s and the P-value was set at 0.05. 
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the protein partners as presented in Table 4. The p-value 
is the probability that the chosen gene for any of the three 
GO term categories occurred by chance. Therefore, a low 
p-value corresponds to a greater likelihood of significance 
set at the false discovery rate (FDR) <0.01. The AURKA 
associated proteins are mainly involved in all three 
GO term categories in BP ontology (cell division), MF 
ontology (protein binding), and CC ontology (spindle). 
KEGG pathway indicated that the AURKA and associated 
genes were mainly enriched in pathways such as cell 
cycle, progesterone-mediated oocyte maturation, oocyte 
meiosis, and p53 signaling pathway.
Receptor and ligand structure preparation and 
docking 
The hAgo2, microRNA, and microRNA-AURKA 
were considered for the molecular docking analysis in 
order to evaluate the mechanism of regulation of AURKA 
in BC (Figure 7). The concept of ligand preparation was 
to produce corresponding low energy 3D structures from 
the format generated from RNA-composer with the option 
to expand each input structures by generating variation on 
the ionization states, tautomers, stereochemistry and ring 
conformation (Figure 7A and 7B). The ligands (hsa-miR-32-
Figure 2: mRNA expression of AURKA in BC subtypes (Oncomine database). The three datasets (A) and the BC subtypes 
(B). Note: Curtis Breast Statistics: 0. Breast (B); 1. Benign Breast Neoplasm (BBN); 2. Breast Carcinoma (BC); 3. Breast Phyllodes Tumor 
(BPT); 4. Ductal Breast Carcinoma in situ (DBCi); 5. Invasive Breast Carcinoma (IBC); 6. Invasive Ductal Breast Carcinoma (IDBC); 7. 
Invasive ductal and invasive lobular breast carcinoma; 8. invasive lobular Breast Carcinoma; 9. Medullary Breast Carcinoma (MBC); 10. 
Mucinous Breast Carcinoma (MuBC); 11. Tubular Breast Carcinoma (TCB). Zhao Breast Statistics: 0. Breast; 1. Invasive ductal BC; 2. 
Lobular BC. TCGA Breast Statistics: 0. Breast; 1. Apocrine Breast Carcinoma; 2. Breast Large Cell Neuroendocrine Carcinoma; 3. Ductal 
Breast Carcinoma; 4. Intraductal Cribriform Breast Carcinoma; 5. Invasive Breast Carcinoma; 6. Invasive Cribriform Breast Carcinoma; 
7. Invasive Ductal Breast Carcinoma; 8. Invasive Ductal and Lobular Carcinoma; 9. Invasive Lobular Carcinoma; 10. Invasive Papillary 
Breast Carcinoma; 11. Male Breast Carcinoma; 12. Metastatic Breast Carcinoma; 13. Mixed Lobular and Ductal Breast Carcinoma; 14. 
Mucinous Breast Carcinoma; 15. Papilary Breast Carcinoma; 16. Pleomorphic Breast Carcinoma.
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3p and microRNA-AURKA duplex) were prepared using 
LigPrep, a module in Maestro (Figure 7C). The receptor, 
hAgo2 was prepared and verified by Schrodinger suite and 
PDBSum PROCHEK, respectively (Figure 7D and 7E). 
Briefly, Protein preparation module in Schrodinger (Maestro 
v12.2) was employed to ascertain the readiness of the protein 
for docking by the following steps: (a) Pre-processing (basic 
task): Assignment of bond orders, filling of missing side 
chains and loops by prime, and deletion of water molecules 
beyond 5 Å from het groups; (b) Review and modification: 
inspection and correction of ionization and the tautomeric 
state of the het groups present in the receptor using Epik at a 
target pH range of 7.0+/–2.0; (c) Refinement: Optimization 
of the orientation of hydrogen bond network (PROPKA at 
pH 7.0) and structural restrained minimization by force field 
Optimized Potentials for Liquid Simulations (OPLS_2005) 
at root mean square deviation (RMSD) of 0.30 Å. As shown 
in Figure 7D, the crystal structure of hAgo-2 which was used 
in this study was stable and obeyed theoretical predication. 
Molecular docking analysis
Docking analysis 
PatchDock web-based docking algorithm was 
employed for the docking profile of AURKA and hAgo-
2 alongside miR-32-3p. The PDB file of hAgo-2 protein 
and the ligands were used as inputs with clustering 
RMSD of 1.5 Å. The generated complexes were based 
on their geometric shape complementarity score. The 
results with the highest score were chosen for each of the 
ligands and hAgo-2 (Table 5). The binding affinity of the 
complex was assessed through their binding scores, and 
interacting amino acid residues between the ligands and 
the receptor protein (Tables 6 and 7 and Figures 8 and 9). 
The result revealed that hAgo-2 protein formed 10 pairs of 
hydrogen bonds and 3 pairs of Pi interactions with miR-
32-3p-AURKA duplex with 59 amino acids involved in 
the binding cavity of the hAgo-2 protein compared to the 
40 amino acids residues found in the pocked of hAgo-2 
protein when interacting with miR-32-3p and six pains of 
hydrogen bonds which demonstrated the complexes are 
highly stable. 
DISCUSSION
The process of carcinogenesis and therapeutic 
responses present a terrific challenge to favorable 
therapeutic outcome [41]. However, identifying cancer 
specific targets can pave the way for effective treatment 
options against specific cancer types [42]. Computational 
approaches are extensively used to investigate molecular 
and genetic mechanism of cancer progression by 
identifying lead genes and the abnormal regulatory 
pathways of disease [43]. In cancer research, these 
methods have revealed molecular targets for therapeutic 
intervention and cancer mechanisms (development, 
progression, or metastasis) in a systematical, accurate 
and effective manner [44]. Additionally, due to cancer 
complexity, it is crucial to investigate the molecular basis 
and identify significant therapeutic targets of this disease. 
Table 4: Functional and pathway enrichment analysis of AURKA and its associated genes (DAVID)
Category Term Count % p-value
GOTERM_BP_DIRECT cell division 8 72.7 1.80 × 10-10
GOTERM_BP_DIRECT mitotic nuclear division 7 63.6 2.00 × 10-09
GOTERM_BP_DIRECT G2/M transition of mitotic cell cycle 6 54.5 8.20 × 10-09
GOTERM_BP_DIRECT anaphase-promoting complex-dependent catabolic process 5 45.5 9.30 × 10-08
GOTERM_BP_DIRECT regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle 4 36.4 2.70 × 10-07
GOTERM_CC_DIRECT spindle 5 45.5 3.80 × 10-07
GOTERM_CC_DIRECT microtubule cytoskeleton 5 45.5 6.20 × 10-07
GOTERM_CC_DIRECT spindle microtubule 4 36.4 1.60 × 10-06
GOTERM_CC_DIRECT nucleoplasm 9 81.8 9.90 × 10-06
GOTERM_CC_DIRECT spindle pole 4 36.4 2.40 × 10-05
GOTERM_MF_DIRECT protein binding 11 100 1.50 × 10-03
GOTERM_MF_DIRECT anaphase-promoting complex binding 2 18.2 3.50 × 10-03
GOTERM_MF_DIRECT ATP binding 5 45.5 8.30 × 10-03
GOTERM_MF_DIRECT protein kinase activity 3 27.3 1.80 × 10-02
GOTERM_MF_DIRECT protein serine/threonine kinase activity 3 27.3 2.00 × 10-02
KEGG_PATHWAY Oocyte meiosis 5 45.5 2.20 × 10-06
KEGG_PATHWAY Cell cycle 4 36.4 1.90 × 10-04
KEGG_PATHWAY Progesterone-mediated oocyte maturation 3 27.3 3.20 × 10-03
KEGG_PATHWAY p53 signaling pathway 2 18.2 6.60 × 10-02
Note: BP: biological process; CC: cellular component; MF: molecular process. Gene enrichment.
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Recently, researches aimed at identifying the mode of 
action of BC have increased. Numerous therapeutic 
interventions have been developed [45]. Nevertheless, 
these strategies induce a range of therapeutic responses 
and resistance can develop in BC patients, therefore novel 
therapeutic intervention is desirable.
Due to the importance of microRNAs in 
carcinogenesis, they suggest potential alternative 
therapeutic targets for cancer [46]. Specifically, Polini 
et al. [47] revealed the tumor suppressive role of miR-
193a and further suggested that their expression could 
be attributed to novel treatment for cutaneous melanoma 
patients.
In this study, the role of AURKA gene expression 
with clinicopathological details was investigated using 
in silico and molecular docking study and proposed 
that the expression of AURKA gene may be regulated 
by miR-32-3p through RNA induced silencing complex 
in BC. AURKA is a serine/threonine kinase involved in 
the regulation of mitotic chromosomal segregation and 
centrosome function. The conservation of AURKA gene 
has been previously reported in various species including 
Table 5: The docking scores between microRNA, microRNA-AURKA duplex and hAGO-2 protein
Category Score Area ACE No of AAs
miR-32-hAgo2 16038 3113.20 –434.34 40
Duplex-hAgo2 24104 4130.40 –379.12 59
Note: ACE: Atomic contact energy; Duplex-hAgo2: microR-32-AURKA-hAgo2; hAgo2: human argonaute 2. The score 
indicates the geometric shape complementary score and atomic contact energy (ACE) score generated for microRNA-hAgo2 
complex and duplex-hAgo-2 complex. 
Figure 3: The prognostic value of mRNA level of AURKA in BC patients (Kaplan–Meier plotter). Notes: The OS, PPS, 
DMFS, and RFS survival curve comparing the patient with high (red) and low (black) AURKA expression in BC were plotted from 
Kaplan–Meier plotter database as the threshold of P-value < 0.05, respectively. Endpoints Affymetrix IDs: 208079_s_at. Abbreviations: 
OS: overall survival; PPS: progression free survival; RFS: relapses free survival; DMFS: distance metastasis free survival.
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human [48]. Based on its critical role in cancer biology, 
it may be of great importance to evaluate the status for 
selecting the most effective therapeutic options most 
especially in BC. 
To evaluate whether a gene have therapeutic target 
potential, it often needs to be uniquely expressed or 
highly expressed in tumors than in most normal tissues. 
Gene expression profiles of 434 total unique analyses 
in Oncomine were employed to perform bioinformatics 
analysis in this study. The expression of AURKA was 
significantly over-expressed in 11 out of 12 BC datasets. The 
overexpression could be correlated with high occurrence 
of BC [49, 50]. This result was validated by GEPIA and 
the mRNA expression level of AURKA was found to be 
significantly upregulated in BC than normal breast tissues. 
Studies have shown that AURKA is involved in multiple 
mechanisms-associated with cancer initiation [51]. 
AURKA overexpression was also suggested to increase 
the expression of MMP-2, MMP-7, MMP-9, leading to 
tumor metastasis by degrading extracellular matrix proteins 
[52–54]. Zhong et al. [55] identified AURKA as potential 
therapeutic targets in glioblastoma-bearing rats. Therefore, 
AURKA is an attractive target for cancer therapy.
The transcription levels of AURKA in different BC 
types were remarkably higher than those in normal tissues, 
and associated with poorer OS, PPS, DMFS, RFS, and 
DFS. As evident, the overall clinicopathological features 
in this study shows that overexpression of this gene was 
correlated with poor survival. Interestingly, high levels of 
AURKA was associated with poor OS and DMFS in ER 
status, PR status, HER2 status, grade stage I and II, and in 
wide-TP53-type BC patients. 
Protein-protein interaction (PPi) network analysis 
demonstrated other 10 significant genes correlated with 
AURKA. To further clarify the mechanism of AURKA, 
a network was constructed for AURKA and the 10 
neighboring genes. GO and KEGG analyses indicated 
that these genes were mainly enriched in a number of GO 
terms. The functional and pathway enrichment analyses 
were highly consistent with the findings that p53 signaling, 
cell cycle and cell division ontology functions were 
regulated abnormally in BC [56]. This study contributed 
to the growing evidence regarding the correlated signaling 
pathway of AURKA which could offer great opportunity 
into the development of biomarkers for the diagnosis and 
prognosis of BC.
Phosphorylation/dephosphorylation have been 
reported as the two predominant mechanisms regulating 
AURKA [57]. The gene was phosphorylated at three 
amino acid residues, Serine-53, Threonine-295, and 
Serine-349. Mutation in the amino acid residues 
Threonine-295 and Serine-349 is associated with reduced 
activity. Phosphorylation of Threonine-295 is required for 
protein kinase (PKA) activation which then phosphorylate 
(Threonine-295) and activate the kinase in vitro [58]. 
Protein phosphatase-1 negatively regulates Aurora A 
Table 6: Molecular docking analysis results of the ligands and receptor with participating aa 
residues (3.5 Å)
Category AA involved Aromatic AA Hydrophobic AA AA-H-bonds




















AA; amino acid. Total hydrophobic residual amino acid involved in docking interaction.
Oncotarget4315www.oncotarget.com
by dephosphorylating T288 [59]. Additionally, studies 
show that ncRNAs regulate gene expression by guiding 
Argonaute proteins to complementary sites on target 
RNA molecules [60–63]. The expression of microRNAs 
has been reported in cancers [64–69]. Specifically, 
microRNAs such are miR-346 and miR-361-3p were 
suggested to modulate the expression of PSA, TMPRSS2 
and DRG1 in prostate cancer [70].
The first microRNA to be reported in the 
dysregulation of BC was in 2005 [71]. The miR-155 
expression was upregulated in BC, its expression was 
associated with clinicopathological markers, tumor 
subtype, and poor survival rates [72, 73]. MiR-665 
expression was also reported to predicts poor survival and 
promotion of tumor metastasis by targeting NR4A3 in 
BC [74]. In addition, deletion of CRISPR/Cas9 suggested 
the oncogenic roles of miR-23b and miR-27b in BC [75]. 
Mature microRNAs assist AGO by guiding the complex 
to target sites in mRNAs that are partially complementary 
to the microRNA sequence (the seed region) [76], and 
induce repression of gene expression at the level of 
mRNA stability or translation [77]. Several proteins 
interfere with mRNA degradation and translational 
repression, some of them are necessary components of the 
RNA induced silencing complex (RISC) that transports 
those microRNAs to complementary sites within mRNA 
[78]. The human AGO-2 is a member of the AGO 
subfamily that is commonly expressed and associate with 
microRNAs. Although different classes of ncRNAs have 
different biogenesis pathways and exert diverse functions, 
all of them must associate with any AGO subfamily for 
activity [77].
Expression of AURKA among other genes was 
directly inhibited by miR-186 in neuroblastoma cells 
[79]. The epigenetic regulation of AURKA by miR-4715-
3p has also been reported in gastrointestinal cancers using 
in silico prediction [23]. MicroRNA-490-3p suppresses 
hepatocellular carcinoma cell proliferation and migration 
by targeting AURKA [80]. Importantly, the expression 
of miR-32-3p has been reported to suppress AURKA but 
the mechanism of action deserves closer attention at both 
atomic and molecular levels [19]. The possible regulation 
of AURKA expression was investigated at both atomic 
and molecular level by evaluating the binding interaction 
between miR-32-hAgo-2 complex and miR-32-AURKA 
duplex bound hAgo-2 using molecular docking study. 
The pool of microRNAs targeting AURKA was 
assessed by TargetScan. Furthermore, their minimum 
folding energy as well as their scores were carried 
out by miRTarBase database. The result showed that 
miR-32 has the highest score of 164.00 and the lowest 
minimum energy of -14.20 kcal/mol. This microRNA 
was further evaluated for its binding activity against 
AURKA gene using molecular docking analysis. For the 
secondary folding analysis, determined by the RNAfold, 
the minimum folding energy (MFE) of the microRNA 
and microRNA-AURKA duplex were -1.70 kcal/mol 
and -3.40 kcal/mol, respectively. Three properties 
(composition, sequence length, and conformation) have 
been reported to be significant to RNA molecule [81]. 
Table 7: Hydrogen bonds and their respective residues between the ligands and receptor within 
the distance of 2 Å
Complex AA residue Atoms Nucleic acid residue Distance
MicroRNA-hAgo2
SER828 HG - O2 C21 1.9
GLU821 O - H3 U4 1.9
THR830 H - OP2 A22 1.3
ASP823 O - H22 G5 1.9
LYS550 HE2 - O5′ A15 1.9
ASP499 OD1 - H5′′ U4 2.0
HIS829 O - H8 A22 1.6
Duplex-hAgo2
ARG69 H – O4 U39 1.7
ARG287 HE - O2 U22 2.0
GLU826 O - HO2′ G18 1.9
ARG286 HD2 - O3′ U22 1.4
ASP252 OD2 - H1′ U19 1.7
LYS65 O – H5 U37 2.0
SER828 HB2 - O2′ G18 1.8
SER824 OG - H1′ U4 2.0
GLU821 OE1 - H2′ U4 1.9
GLU821 OE2 - H5′ U5 1.6
PRO523 O - H8 A7 1.9
Note: AA: amino acid. Criteria, such as strong hydrophobic amino acids together with aromatic amino acids, are important to binding interactions in terms 
of the stability between protein receptors and their ligands.
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Trotta [81] reported that longer sequences are more 
stable due to their ability to form stacking and hydrogen 
bond interactions. Sequence arrangement is also another 
determining factor that affects the folding structure 
stability. The low MFE of the microRNA was justified 
by the sequence length of 22 nucleotides and the number 
of loops formed. The duplex sequence length of 45 
nucleotides and extension of loops, are great advantages 
to confer stability for possible regulation. 
In nature, the stability of molecular binding 
interactions between ligand and its corresponding 
receptor depends largely on specific amino acids 
involved (hydrophobic and aromatic amino acid). The 
interaction between miR-32 and miR-32-AURKA 
duplex and the human argonaute protein were evaluated 
through these aforementioned amino acid residues 
observed in the binding cavity within specific distance. 
The result revealed the presence of specific interactive 
Figure 4: Survival analysis of AURKA in BC. The meta-analysis of the hazard ration with their p-values (A), and the four end points 
pictorial images from PrognoScan database. (B) The survival curves depict the high (Red) and low (blue) expressions with the datasets and 
endpoints. Abbreviations: OS: overall survival; DFS: disease free survival; RFS: relapses free survival; DMFS: distance metastasis free 
survival; HR: hazard ratio.
Figure 5: Intrinsic molecular subtype of AURKA in BC patients (bc-GenExMiner v4.4). The box plots are based on Intrinsic 
molecular subtype of AURKA. Correlation between AURKA expression and genetic information in BC patients. The significant different 
between groups was assessed by Welch’s test to generate p value, along with Dunnett-Tukey-Kramer’s and the P-value was set at 0.05.
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residues of hAgo-2 involved in binding of the ligands. 
Also hydrogen bonds were observed between the 
interaction atoms of the receptor and the ligands. These 
interactions taken together, may be important and thus 
confer regulation of AURKA gene most especially in BC. 
Furthermore, the number of hydrogen bonds involved in 
the interacting atoms of hAgo-2 and miR-32-AURKA 
complex together with the amino acid residues involved 
in binding, and number of important amino acids such 
as hydrophobic and aromatic amino in the cavity of 
hAgo-2 are significantly higher compared to the binding 
interaction observed in miR-32-hAgo-2 complex. This 
Figure 6: The protein interaction network of genes associated with AURKA (STRING in Cytoscape).
Figure 7: The structural models of microRNA and microRNA-AURKA duplex. The dot-bracket notations are colored by 
base-pairing probability (A), the secondary structures are colored by positional entropy (B), the 3D structures were modeled and visualized 
by DSV v19 (C), the Ramachandra plot of the prepared hAgo2 receptor was verified by PDBSum PROCHEK. The area marked with green 
arrows are residues in the most favored region while the regions marked with teal arrows are residues in additional allowed region (D) and 
the 3D model of the prepared hAgo2 was done by Maestro v12.2 (E).
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could therefore, confer stability to the binding of hAgo-2 
to AURKA for better regulation.
MATERIALS AND METHODS
Expression analysis of AURKA
Web-based data-mining platforms were used to 
evaluate the expression (Oncomine) of AURKA and 
further validated using Gene Expression Profiling 
Interactive Analysis (GEPIA-2) database. Oncomine is a 
database that contains cancer microarrays from genome-
wide expression analyses [82], available at https://www.
oncomine.org/. Expression of AURKA was assessed in 
twenty cancer types and their normal counterparts, and 
also compared among BC subtypes relative to normal 
clinical mRNA datasets. Only expression that showed a 
2-fold difference between cancer and normal tissues, a 
p-value of 1.0 × 10-6, and a priority of 5% were considered. 
The mRNA levels of AURKA in BC at a p-value 
less than 0.05 were validated by GEPIA-2 database at 
http://gepia2.cancer-pku.cn/#analysis. TCGA and GTEx 
datasets were used to match the tumor as normal data at 
the cutoff of |Log2FC|of 1.
Prognosis and expression correlation of AURKA 
The statistical exploratory database (Breast cancer 
Gene expression Miner v4.5) assessed at http://bcgenex.
centregauducheau.fr/BC-GEM/GEM-requete.php consists 
Figure 8: Molecular docking result of miR-32 and hAgo2. The binding position of the miR-32 in the pocket of hAgo2 (A); 
Residual amino acids participating in their interaction (B); Amino acid residues (C).
Figure 9: The docking result of miR-32-AURKA and hAgo2. The binding position of the complex in the pocket of hAgo2 (A); 
Residual amino acids participating in their interaction (B); Amino acid residues (C). 
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of BC transcriptomic data (10, 0001 DNA microarrays 
and 4, 712 RNA-seq) [37, 83]. This software offers the 
possibility to explore expression of genes of interest in BC 
and the statistical analyses are categorized as correlation, 
expression and prognosis. This tool was used to study 
the AURKA expression in BC, the correlation between 
AURKA mRNA levels and clinicopathological features in 
BC clinical dataset (Probe set ID: 208079_s_at). 
Survival analysis of AURKA in BC
The Kaplan-Meier database (KM-plot) is a manually 
curated web-based tool handled by a PostgreSQL 
server assessed at https://kmplot.com/analysis/index.
php?p=service&cancer=breast. This plotter is composed of 
gene expression and clinical data, and is used to evaluate 
the prognostic value of a biomarker. The expression 
of AURKA gene in BC patients in relation to survival 
rate was analyzed by KM-plot as a function of log-rank 
p-value, and the hazard ratio of 95% confidence intervals. 
The database can assess 54, 000 cancer-linked genes from 
21 cancer types, with breast as the largest dataset [84]. 
This database is a repository for the meta-analysis based 
on the discovery and validation of biomarkers from the 
cancer survivors [85]. 
Prognostic and meta-analysis of AURKA in BC 
(PrognoScan)
PrognoScan is a web-based tool for meta-analysis 
of prognostic value of genes. With its relatively simple 
user interface, it correlates gene expression with patient 
prognosis on the available cancer microarray datasets. 
Advantages of this tool include its large collection 
of publicly available cancer microarray datasets with 
clinical annotation and the assessment of the biological 
relationship between gene expression and prognosis. 
Furthermore, it utilizes the minimum p-value approach for 
classifying patients for survival analysis that evaluates the 
optimal cutpoint in continuous gene expression estimation 
without prior biological knowledge or assumption and 
therefore, enables systematic meta-analysis of numerous 
datasets [86]. This tool assessed at http://dna00.bio.
kyutech.ac.jp/PrognoScan/ was used to evaluate AURKA 
as a potential biomarker and a possible BC therapeutic 
target.
AURKA interaction analysis (STRING and 
Cytoscape)
The Search Tool for the Retrieval of Interacting 
Genes (STRING) database accessed at http://www.string-
db.org/ provides extensive view of pre-existing, predicted 
interactions, and their associated proteins. To explore the 
co-expressed protein alongside AURKA gene, the proteins 
that associates with the AURKA gene was predicted and 
visualized by Cytoscape at http://www.cytoscape.org/. The 
output of this analysis is an interaction network showing 
various interacted genes as nodes. The AURKA node 
was taken as the “hub” genes in the protein network at a 
confidence level of 0.90. Additionally, the visual display 
was then adjusted (nodes, edges, and network) using 
appropriate layout and plugins to achieve a less dense/ 
clustered image. An additional interaction was further 
produced to evaluate their specificity to BC.
Functional enrichment and pathway analysis
Standard gene IDs for a list of genes identified by 
STRING associated with AURKA were used as input 
in database for annotation, visualization and integrated 
discovery (DAVID database) in order to examine the 
gene functions and disease pathways by annotation of the 
protein partners alongside AURKA gene. This database 
was accessed at https://david.ncifcrf.gov/summary.jsp. 
The web-based tool displays the annotation summary 
results with several options. For the link gene-disease 
associations, the GAD_DISEASE was prioritized. The 
observed result ranked the AURKA-associated genes 
in different cancer types and processes with the special 
emphasis on the BC for this study. The gene ontology 
and pathway analysis were further analysed using this 
database.
Dataset selection and docking study
Datasets
MiRTarBase v8.0 at http://mirtarbase.mbc.
nctu.edu.tw/ is a freely available web-based tool for 
microRNA-gene interactions. These interactions were 
experimentally validated through molecular assays; 
MiRTarBase contains the largest microRNA to targets 
interactions (MTIs) datasets. Additionally, this tool 
provides the up to date MTIs collection which are 
cross referenced with other related databases [87]. The 
target microRNA sequence of AURKA was predicted 
by miRanda v10. This tool was used to retrieve the 
microRNA, and microRNA-target interaction sequences 
for downstream analysis. 
The TargetScanHuman v7.2 is a microRNA 
target prediction tool that predicts the molecular 
targets for microRNAs that matches the 8mer, 7mer, 
and 6mer conserved regions in the seed region of each 
microRNA (http://www.targetscan.org/vert_72/) [88]. 
TargetScanHuman was used to confirm the target of the 
microRNA of interest.
RNAfold database at http://rna.tbi.univie.ac.at//cgi-
bin/RNAWebSuite/RNAfold.cgi was used to predict the 
secondary structures, the minimum folding energy and 
doc-bracket notations of the microRNA and microRNA-
AURKA duplex with the command line: RNAfold -p -d2 
Oncotarget4320www.oncotarget.com
--noLP < sequence1.fa > sequence1.out. Furthermore, 
RNA-composer, a fully automated RNA structure 
modeling server at http://rnacomposer.cs.put.poznan.pl/ 
was used to generate a 3D PDB file format of the doc-
bracket notations [89]. The crystal structure of (hAgo2) 
(PDB ID: 4F3T; resolution: 2.25 Å) was retrieved through 
the Protein Databank (PDB) for docking analysis.
Protein preparation, docking, and visualization 
analyses
The molecular docking analysis of AURKA and 
microRNA of interest was performed by Schrodinger suite, 
PATCHDOCK, and Discovery Studio Visualizer (DSV) 
following the approach described by Fadaka et al. [90].
Statistical analysis
The graph pad prism 6.0 software was used to 
analyze all the data in this study. Specifically, ANOVA 
and Student’s t-test were utilized to compute the clinical 
data between tests and controls. The ratio of the groups 
was correlated by the chi-square test. The odds ratio and 
95% confidence interval were determined to assess the 
relationship between the gene of interest and BC risk 
through logistic analysis. All values were considered 
statistical significant at p < 0.05.
CONCLUSIONS
The expression level of AURKA was significantly 
upregulated in patients with BC. Aberrant AURKA 
expression was found to be associated with poor prognosis 
of BC. The interactions observed within the distance of 
3.5 Å and the hydrogen bonds within the distance of 
2.0 Å were supportive that AURKA regulation through 
the AGO protein could be driven by miR-32-3p.  These 
observed interactions are crucial to protein folding, 
stability and in the binding of targets. Based on the past 
and recent research on the roles of ncRNAs in the field of 
cancer, it can be inferred that therapeutics associated with 
microRNAs could provide desired therapeutic outcomes in 
cancer patients and related diseases. This study therefore, 
provides insight into the mode of AURKA regulation 
by miR-32-3p in BC. Formulations with ncRNAs can 
be more effective as therapeutic approaches and may 
represent a novel therapeutic intervention in BC and other 
cancer subtypes.
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